Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

407 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Feasibility of CD19 CAR T-cell therapy in patients with cardiac lymphoma.
Kuipers MT, Spanjaart AM, Bonifazi F, diBlasi R, Zinzani PL, Thieblemont C, Baudet M, Biemond BJ, Kok WEM, Kersten MJ. Kuipers MT, et al. Among authors: thieblemont c. Leuk Lymphoma. 2024 Mar;65(3):399-402. doi: 10.1080/10428194.2023.2288804. Epub 2023 Dec 9. Leuk Lymphoma. 2024. PMID: 38069804 No abstract available.
Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations.
Rejeski K, Subklewe M, Aljurf M, Bachy E, Balduzzi A, Barba P, Bruno B, Benjamin R, Carrabba MG, Chabannon C, Ciceri F, Corradini P, Delgado J, Di Blasi R, Greco R, Houot R, Iacoboni G, Jäger U, Kersten MJ, Mielke S, Nagler A, Onida F, Peric Z, Roddie C, Ruggeri A, Sánchez-Guijo F, Sánchez-Ortega I, Schneidawind D, Schubert ML, Snowden JA, Thieblemont C, Topp M, Zinzani PL, Gribben JG, Bonini C, Sureda A, Yakoub-Agha I. Rejeski K, et al. Among authors: thieblemont c. Blood. 2023 Sep 7;142(10):865-877. doi: 10.1182/blood.2023020578. Blood. 2023. PMID: 37300386 Free article. Review.
Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study.
Opat S, Tedeschi A, Hu B, Linton KM, McKay P, Leitch S, Coleman M, Zinzani PL, Jin J, Sun M, Sobieraj-Teague M, Browett P, Ke X, Thieblemont C, Ardeshna K, Bijou F, Walker P, Hawkes EA, Ho SJ, Zhou K, Liang Z, Xu J, Tankersley C, Delarue R, Co M, Trotman J. Opat S, et al. Among authors: thieblemont c. Blood Adv. 2023 Nov 28;7(22):6801-6811. doi: 10.1182/bloodadvances.2023010668. Blood Adv. 2023. PMID: 37682792 Free PMC article. Clinical Trial.
[No title available]
[No authors listed] [No authors listed] PMID: 39112160
Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma.
Nastoupil LJ, Hess G, Pavlovsky MA, Danielewicz I, Freeman J, García-Sancho AM, Glazunova V, Grigg A, Hou JZ, Janssens A, Kim SJ, Masliak Z, McKay P, Merli F, Munakata W, Nagai H, Özcan M, Preis M, Wang T, Rowe M, Tamegnon M, Qin R, Henninger T, Curtis M, Caces DB, Thieblemont C, Salles G. Nastoupil LJ, et al. Among authors: thieblemont c. Blood Adv. 2023 Nov 28;7(22):7141-7150. doi: 10.1182/bloodadvances.2023010298. Blood Adv. 2023. PMID: 37722354 Free PMC article. Clinical Trial.
T cell malignancies after CAR T cell therapy in the DESCAR-T registry.
Dulery R, Guiraud V, Choquet S, Thieblemont C, Bachy E, Barete S, Todesco È, Arnulf B, Boissel N, Baruchel A, Bay JO, Le Gouill S, Houot R. Dulery R, et al. Among authors: thieblemont c. Nat Med. 2025 Jan 8. doi: 10.1038/s41591-024-03458-w. Online ahead of print. Nat Med. 2025. PMID: 39779930
Is CAR T a drug or a therapeutic pathway? Intention to treat versus per protocol analysis of real world studies of CAR-T cell therapy in relapsed refractory diffuse large B cell lymphoma.
Di Staso R, Casadei B, Locke FL, Jain M, Voorhees TJ, Kittai AS, Bastos-Oreiro M, Gutiérrez A, Martin Garcia-Sancho A, Terol MJ, Mead M, Maranzano MJ, Iacoboni G, Barba P, Kwon M, Bailen R, Reguera-Ortega JL, Mian A, Hill B, Bachy E, Morschhauser F, Houot R, Thieblemont C, Le Gouill S, Masetti R, Gori D, Broccoli A, Zinzani PL, Argnani L. Di Staso R, et al. Among authors: thieblemont c. Blood Cancer J. 2024 Nov 7;14(1):197. doi: 10.1038/s41408-024-01183-8. Blood Cancer J. 2024. PMID: 39511146 Free PMC article. No abstract available.
Precautions to Consider in the Analysis of Prognostic and Predictive Indices.
Chartier L, Belot A, Chaillol I, Elsensohn MH, Portugues C, Fournier M, Joubert C, Gat E, Pizot C, Fogarty P, Murairi T, Ammar RO, Paget J, Cherblanc F, Ricci R, Vercellino L, Kanoun S, Cottereau AS, Thieblemont C, Casasnovas O. Chartier L, et al. Among authors: thieblemont c. J Nucl Med. 2024 Nov 1;65(11):1672-1678. doi: 10.2967/jnumed.123.267021. J Nucl Med. 2024. PMID: 39486863
407 results